Literature DB >> 29862471

JAK Pseudokinase Domain Variants Highlight nRTK VUSs Identified with Next-Generation Sequencing in Solid Tumor Patients.

Matthew K Stein1,2, Lindsay K Morris3, Mike G Martin4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29862471     DOI: 10.1007/s12253-018-0443-3

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


× No keyword cloud information.
  4 in total

1.  Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma.

Authors:  Cristina Pérez; Julia González-Rincón; Arantza Onaindia; Carmen Almaráz; Nuria García-Díaz; Helena Pisonero; Soraya Curiel-Olmo; Sagrario Gómez; Laura Cereceda; Rebeca Madureira; Mercedes Hospital; Dolores Suárez-Massa; José L Rodriguez-Peralto; Concepción Postigo; Alicia Leon-Castillo; Carmen González-Vela; Nerea Martinez; Pablo Ortiz-Romero; Margarita Sánchez-Beato; Miguel Á Piris; José P Vaqué
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

2.  Structural modeling of JAK1 mutations in T-cell acute lymphoblastic leukemia reveals a second contact site between pseudokinase and kinase domains.

Authors:  Kirsten Canté-Barrett; Joost C M Uitdehaag; Jules P P Meijerink
Journal:  Haematologica       Date:  2016-01-27       Impact factor: 9.941

3.  Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.

Authors:  Patrick J Lupardus; Mark Ultsch; Heidi Wallweber; Pawan Bir Kohli; Adam R Johnson; Charles Eigenbrot
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-19       Impact factor: 11.205

4.  A method and server for predicting damaging missense mutations.

Authors:  Ivan A Adzhubei; Steffen Schmidt; Leonid Peshkin; Vasily E Ramensky; Anna Gerasimova; Peer Bork; Alexey S Kondrashov; Shamil R Sunyaev
Journal:  Nat Methods       Date:  2010-04       Impact factor: 28.547

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.